|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
60,850,000 |
Market
Cap: |
5.84(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.05 - $0.096 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Co. focuses on targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are vital to normal and effective function of the brain and nervous system. Co. is developing a pipeline of product candidates derived from its NMDAr modulator discovery platform, or the discovery platform: NYX-2925 for the treatment of chronic pain; NYX-783 for the treatment of post-traumatic stress disorder; and NYX-458 for the treatment of cognitive impairment.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hombach Robert J. |
Director |
|
2019-11-22 |
4 |
B |
$3.24 |
$161,750 |
D/D |
50,000 |
89,100 |
2.39 |
- |
|
Gosebruch Henry O |
Director |
|
2019-10-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
100,000 |
100,000 |
|
- |
|
Gosebruch Henry O |
Director |
|
2019-10-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
100,000 |
0 |
|
- |
|
Gosebruch Henry O |
Director |
|
2019-05-08 |
4 |
B |
$3.86 |
$372,799 |
D/D |
96,580 |
100,000 |
2.39 |
- |
|
Gosebruch Henry O |
Director |
|
2019-05-07 |
4 |
B |
$3.75 |
$12,825 |
D/D |
3,420 |
3,420 |
2.39 |
- |
|
Madsen Torsten M. |
Chief Medical Officer |
|
2019-01-28 |
4 |
B |
$5.27 |
$5,534 |
D/D |
1,050 |
232,600 |
2.74 |
- |
|
Hombach Robert J. |
Director |
|
2019-01-25 |
4 |
B |
$5.54 |
$64,569 |
D/D |
11,655 |
49,100 |
2.39 |
- |
|
Hombach Robert J. |
Director |
|
2019-01-24 |
4 |
B |
$5.52 |
$73,664 |
D/D |
13,345 |
37,445 |
2.39 |
- |
|
Khanna Ashish |
CFO and CBO |
|
2019-01-18 |
4 |
B |
$5.45 |
$54,500 |
D/D |
10,000 |
283,130 |
2.74 |
- |
|
Riedel Norbert G |
CEO and President |
|
2018-11-12 |
4 |
OE |
$2.59 |
$99,878 |
D/D |
38,563 |
362,539 |
|
- |
|
Koppel Adam |
Director |
|
2018-06-25 |
4 |
B |
$16.00 |
$6,400,000 |
I/I |
400,000 |
2,225,092 |
2.1 |
- |
|
Koppel Adam |
Director |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,825,092 |
1,825,092 |
|
- |
|
Adams Street Partners Llc |
10% Owner |
|
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
1,115,910 |
1.5 |
- |
|
Adams Street Partners Llc |
10% Owner |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,077 |
1,063,439 |
|
- |
|
Ratcliffe Liam |
Director |
|
2018-06-25 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
368,345 |
2.25 |
- |
|
Ratcliffe Liam |
Director |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
243,345 |
|
- |
|
Khanna Ashish |
CFO and CBO |
|
2018-06-25 |
4 |
B |
$16.00 |
$28,800 |
I/I |
1,800 |
1,800 |
1.99 |
- |
|
Khanna Ashish |
CFO and CBO |
|
2018-06-25 |
4 |
B |
$16.00 |
$96,000 |
D/D |
6,000 |
273,130 |
2.74 |
- |
|
Khanna Ashish |
CFO and CBO |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
15,430 |
267,130 |
|
- |
|
New Leaf Bpo Associates I, L.p. |
10% Owner |
|
2018-06-25 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
368,345 |
1.5 |
- |
|
New Leaf Bpo Associates I, L.p. |
10% Owner |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
243,345 |
|
- |
|
Topper James N |
Director |
|
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
3,190,079 |
2.25 |
- |
|
Topper James N |
Director |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,079 |
3,040,079 |
|
- |
|
Gould Terry P |
Director |
|
2018-06-25 |
4 |
B |
$16.00 |
$2,400,000 |
I/I |
150,000 |
1,115,910 |
2.25 |
- |
|
Gould Terry P |
Director |
|
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
3,040,077 |
1,063,439 |
|
- |
|
69 Records found
|
|
Page 2 of 3 |
|
|